On May 12, 2026, Myeloid Cure is hnonored to announce the signing of a joint development cooperation agreement with the MSD R&D China Innovation Collaboration Center. The two parties will collaborate on the clinical co-development of antibody therapeutics in the autoimmune disease space.

As one of the world's leading multinational pharmaceutical companies in healthcare, MSD has long led innovation in the treatment of major diseases and continues to advance breakthrough therapies.

Myeloid Cure Biotechnology is deeply involved in the research and development of original innovative drugs targeting macrophages, and has established a rich matrix of innovation pipeline in key major disease fields such as autoimmune diseases and tumors. The collaboration between the two parties will further accelerate the development of innovative drugs in the field of refractory diseases, ultimately bringing better treatment options to patients worldwide and jointly contributing to the improvement of human health and well-being.

Background and Significance of the Collaboration

As a core innovation practice of MSD's global R&D network, the MSD R&D China Innovation Collaboration Center (MCICC) was officially established in 2024. It is dedicated to building an open, agile and efficient innovation collaboration platform focused on high-potential early-stage projects. Leveraging MSD's global scientific resources and China's local innovation ecosystem strengths, MCICC empowers "China-originated" innovations to benefit patients globally, saving lives and improving quality of life.

MCICC Cooperation Milestones

Since its launch, MCICC has signed 3 cooperation agreements with local innovative Chinese biotech companies, added 2 new letters of intent in May, engaged with over 530 local enterprises in total, and held in-depth discussions with more than 100 of them.

Leadership Remarks

Dr. Li Zhengqing, Senior Vice President of MSD Global and President of MSD China R&D Center, stated: "Myeloid Cure has demonstrated solid scientific foundation and deep innovation expertise in the autoimmune disease field. By combining our respective strengths, we look forward to accelerating the clinical translation of high-quality China-originated innovations."

Dr. Eliav Barr, Global Chief Medical Officer and Head of Clinical Development at MSD, also expressed high expectations for the partnership: "We will work closely together to drive innovation, speed up clinical development, and create value for patients in China and around the world."

Overview of MSD China R&D

Headquartered in Beijing, MSD China R&D Center operates R&D teams in Shanghai, Guangzhou, Chengdu and Wuhan, with research spanning oncology, vaccines, anti-infectives, cardiovascular and metabolic diseases and more. Its oncology research alone covers over 20 cancer types, including several high-incidence cancers in China. To date, MSD has introduced more than 80 innovative medicines, vaccines, new indications and companion diagnostics to China, continuously meeting local clinical needs.

About Myeloid Cure

Founded in December 2019 by a team of returnee and domestic PhD-level researchers, Myeloid Cure Biotechnology Co., Ltd. is headquartered in Xiaoshan KaiFeng Science Park. The company focuses on macrophage immune drug discovery and development, specializing in the R&D and industrialization of global first-in-class (FIC) medicines, with a differentiated pipeline portfolio spanning autoimmune diseases and malignant oncology.

The proprietary Myeloid Phagocytosis Engager (MPE) bispecific antibody platform is a core competitive advantage of Myeloid Cure. Featuring a unique dual mechanism of action, the platform simultaneously enhances Fcγ receptor-mediated antibody-dependent cellular phagocytosis (ADCP) and ADCP-independent phagocytosis, enabling highly efficient clearance of primary B cells and a broad range of tumor cells. Compared with traditional immunotherapies, the MPE platform delivers deeper target cell elimination, offering a novel therapeutic approach for autoimmune diseases and oncology, with the potential to set new global treatment standards.

Outlook

This partnership between Myeloid Cure and MSD represents a deep integration of world-class pharmaceutical resources and China's local innovation power. The two parties will leverage their respective strengths to accelerate the translation of innovative drugs from bench to bedside, contribute to the fight against refractory diseases, and jointly advance human health and well-being.